Immunovant (IMVT) return on equity (ROE)

Return on equity · fiscal 2026
-59.3%

Immunovant (IMVT) earned a return on equity of -59.3% in fiscal 2026 (the year ended March 31, 2026). That is 0.8 percentage points lower than the -58.5% of fiscal 2025. Figures as of 17 Nov 2026, 17:36 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2026
-59.3%
Change on fiscal 2025
−0.8 pts
Highest on record
-27.4%fiscal 2021
Lowest on record
-389.7%fiscal 2019
Fiscal years on record
82019–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Immunovant return on equity (ROE), in more detail

Across the 8 fiscal years on record (2019–2026), the highest was -27.4% in fiscal 2021 and the lowest -389.7% in fiscal 2019. The fiscal 2026 figure is higher than in 29% of the 7 earlier fiscal years on record, whose median is -58.2%.

History · 8 fiscal years

Return on equity by fiscal year

Immunovant return on equity (ROE), year by year

Immunovant (IMVT) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2026-59.3% 0.8 pts down
2025-58.5% 16.5 pts down
2024-42.0% 16.2 pts up
2023-58.2% 24.8 pts down
2022-33.4% 5.9 pts down
2021-27.4% 43.1 pts up
2020-70.6% 319.1 pts up
2019-389.7%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant return on equity (ROE): questions and answers

What is Immunovant's return on equity?

Immunovant (IMVT) earned a return on equity of -59.3% in fiscal 2026 (the year ended March 31, 2026). That is 0.8 percentage points lower than the -58.5% of fiscal 2025.

Is Immunovant's return on equity high or low compared with its own history?

The fiscal 2026 figure is higher than in 29% of the 7 earlier fiscal years on record, whose median is -58.2%.

What are the highest and lowest return on equity figures on record for Immunovant?

Across the 8 fiscal years on record (2019–2026), the highest was -27.4% in fiscal 2021 and the lowest -389.7% in fiscal 2019.

How is Immunovant's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/IMVT/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.